These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3260643)

  • 41. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
    Brenner BG; McCrea EL; Margolese RG
    Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
    Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
    Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Bonavida B; Nio Y; Yoshida O
    Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
    Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
    J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
    Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ
    Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct cytotoxicity against neuroblastoma cells of peripheral blood and tumor-infiltrating lymphocytes from patients with neuroblastoma.
    Kataoka Y; Matsumura T; Yamamoto S; Sugimoto T; Sawada T
    Cancer Lett; 1993 Sep; 73(1):11-21. PubMed ID: 8402593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin 2(R-IL2)].
    Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Kunii Y; Sakata K
    Nihon Geka Gakkai Zasshi; 1988 Jul; 89(7):992-8. PubMed ID: 2975748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cytotoxicity of lymphocytes sensitized by autologous tumor cells in vitro, against autologous lung cancer cell lines].
    Inaba H; Kobayashi S; Okada S; Fujimura S; Nakata T
    Nihon Geka Gakkai Zasshi; 1990 Apr; 91(4):515-23. PubMed ID: 2142996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes.
    Grimm EA; Wilson DJ
    Cell Immunol; 1985 Sep; 94(2):568-78. PubMed ID: 3928175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extravascular natural cytotoxicity in man: Anti-K562 activity of lymph-node and tumour-infiltrating lymphocytes.
    Moore M; Vose BM
    Int J Cancer; 1981 Mar; 27(3):265-72. PubMed ID: 6169658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
    Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
    Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
    Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
    Pisani RJ; Krco CJ; Wold LE; McKean DJ
    Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients.
    Bonilla F; Alvarez-Mon M; Merino F; de la Hera A; Alés JE; España P; Durántez A
    Cancer; 1988 Feb; 61(4):629-34. PubMed ID: 3257405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes].
    Kan N; Okino T; Nakanishi M; Satou K; Mise K; Ohgaki K; Hori T; Kodama H; Tobe T
    Hum Cell; 1988 Sep; 1(3):289-96. PubMed ID: 2979206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The characteristic of lymphokine-activated killer cells induced from tumor draining lymph-node cell].
    Meng YG; Fu CY; Wang YZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):535-7, 574. PubMed ID: 7835130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukin 2 induced non MHC-restricted killing of herpes simplex type-1 (HSV-1) infected allogeneic and autologous lymphoblasts.
    Klimpel GR; Asuncion M; Fons M; Norton JD; Albrecht T; Klimpel KD; Stein MD
    J Clin Lab Immunol; 1989 May; 29(1):1-7. PubMed ID: 2560794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human tumour--lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells.
    Vose BM; Vánky F; Klein E
    Int J Cancer; 1977 Dec; 20(6):895-902. PubMed ID: 591128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.